User profiles for Jordan R. Barrett
 | Jordan R. BarrettGraduate Student, The Scripps Research Institute Verified email at scripps.edu Cited by 12826 |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
More than 190 vaccines are currently in development to prevent infection by the novel severe
acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing …
acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing …
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 …
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
[PDF][PDF] Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Background Development of an effective vaccine against the pathogenic blood-stage infection
of human malaria has proved challenging, and no candidate vaccine has affected blood-…
of human malaria has proved challenging, and no candidate vaccine has affected blood-…
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
MM Hou, JR Barrett, Y Themistocleous… - Science translational …, 2023 - science.org
There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII)…
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII)…
Overcoming symmetry mismatch in vaccine nanoassembly through spontaneous amidation
…, HJ Wu, AMC Andersson, JR Barrett… - Angewandte Chemie …, 2021 - Wiley Online Library
Matching of symmetry at interfaces is a fundamental obstacle in molecular assembly. Virus‐like
particles (VLPs) are important vaccine platforms against pathogenic threats, including …
particles (VLPs) are important vaccine platforms against pathogenic threats, including …
[HTML][HTML] Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5. 1/AS01B malaria vaccine
Modifications to vaccine delivery that increase serum antibody longevity are of great interest
for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing …
for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing …
